Roche Media News

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

8 days ago

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in...

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

22 days ago

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV...

https://www.roche.com/media/releases/med-cor-2026-03-23

28 days ago

Roche launches NVIDIA AI factory to accelerate the development of new therapeutics and diagnostics solutions

about 1 month ago

With the addition of 2,176 NVIDIA Blackwell GPUs, Roche now operates the...

Roche Annual General Meeting 2026

about 1 month ago

Shareholders approved all proposals of the Board of Directors Severin Schwan re-elected...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on phase III persevERA study in ER-positive advanced breast cancer

about 1 month ago

persevERA Breast Cancer study did not meet the primary objective of a...

New England Journal of Medicine publishes phase III ALLEGORY data showing Roche’s Gazyva/Gazyvaro significantly reduces disease activity in the most common form of lupus

about 2 months ago

Over three quarters of people on Gazyva/Gazyvaro plus standard therapy achieved at...

Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity

about 2 months ago

Petrelintide achieved up to 10.7% mean body weight reduction at week 42...

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

about 2 months ago

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses...

FDA accepts New Drug Application for Roche’s giredestrant in ESR1-mutated, ER-positive advanced breast cancer

about 2 months ago

Filing acceptance based on phase III data showing giredestrant plus everolimus reduced...

Change to the Roche Enlarged Corporate Executive Committee

2 months ago

Basel, 17 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today...

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

2 months ago

MAJESTY, the first global phase III study in primary membranous nephropathy, met...